Rising Obesity Rates in U.S. Children and Adolescents

Posted by The Evidence Blog on July 10, 2018

The percentage of children and adolescents affected by obesity has more than tripled since the 1970s, according to the CDC; nearly 1 in 5 American youth are obese. According to data from the National Health and Nutrition Examination Survey, around 18% of youth ages 2 to 19 years were obese and nearly 6% were severely obese in 2015-2016. Rates of obesity and severe obesity in adolescents (ages 12 to 19 years) are even higher.

Read More

FDA Approves First Cannabis-Derived Drug for Treatment of Seizures

Posted by The Evidence Blog on July 5, 2018

The Food and Drug Administration (FDA) last week approved Epidiolex (cannabidiol; GW Pharmaceuticals) for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older. This is the first FDA-approved drug that contains a purified drug substance derived from marijuana; it’s also the first FDA approval of a drug for the treatment of patients with Dravet syndrome.

Read More

Topics: FDA approval, Epidiolex

FDA’s Efforts to Support Value-Based Healthcare

Posted by The Evidence Blog on June 27, 2018

Innovative medical treatments are being developed at an astonishing pace. However, rising medical costs are a roadblock to patient access to many of these innovations. Last month, Secretary of Health and Human Services Alex Azar rolled out a blueprint to address this challenge. The blueprint highlights the importance of linking payments for medical treatments to their value and removing regulatory obstacles to value-based purchasing.

Read More

Topics: FDA, value based healthcare

FDA Approves Palynziq for Treatment of Phenylketonuria

Posted by The Evidence Blog on June 15, 2018

Recently, the FDA approved Palynziq (pegvaliase-pqpz; BioMarin Pharmaceutical Inc.), a phenylalanine-metabolizing enzyme indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations on existing management. 

Read More

FDA Expands Indications for Senhance Surgery System

Posted by The Evidence Blog on June 15, 2018

With the promise of shorter hospital stays, less blood loss, less pain, fewer complications from surgery, and a quicker return to normal activities for most patients, many hospitals and healthcare systems are embracing the use of robotic surgery systems. 

Read More

FDA Approves New Drug to Treat Thrombocytopenia in Chronic Liver Disease

Posted by The Evidence Blog on June 14, 2018

The FDA has approved Doptelet (avatrombopag; AkaRx Inc.), a drug used for the treatment of thrombocytopenia in adult patients with chronic liver disease who have low blood platelets and are scheduled to undergo a medical or dental procedure. This is the first drug approved by the FDA for this use.  

Read More

FDA Approves First-in-Class Medicine for Migraine Prevention

Posted by The Evidence Blog on June 14, 2018

The FDA has approved Aimovig (erenumab-aooe; Amgen and Novartis) for the preventive treatment of migraine in adults. Aimovig is an injectable calcitonin gene-related peptide (CGRP) antagonist.

Read More

Adoptive Immunotherapy the Focus of New Hayes Report

Posted by Paula Goines, PhD, Medical Research Analyst on October 2, 2017

Chimeric antigen receptor (CAR) T cells and genetically engineered T-cell receptor (TCR) T cells have been topics of increasing interest as of late for both payers and providers alike. T cells are targeted, personalized therapies for:

  • solid tumors
  • hematological cancers
  • lymphoproliferative diseases
Read More

Life-Altering Information, or Just For Fun?

Posted by Nancy Ledbetter, Research Analyst on August 22, 2017

Helix, a company formed by Illumina in 2015, has drawn a new section on the blurry line between healthcare and entertainment using direct-to-consumer (DTC) genetic tests. For the surprisingly low price of $80, Helix will sequence a person’s exome, using the same Illumina machines most researchers use. After a one-time saliva submission, Helix clients can choose from a menu of existing analyses from outside vendors that vary from < $100 to about $250. Currently, the Helix website lists 19 different options for clients to learn about their DNA. They include one that uses DNA information to inform which wines are likely to be appealing and another for learning carrier status for a host of mutations that are associated with disease (e.g., cystic fibrosis) for future children if both parents are carriers. As Helix adds more vendors, clients will have the opportunity to order additional analyses to learn more information around their genetic make-up.

Read More

Topics: Hayes Blog, Healthcare Evidence, Genetic Testing, Consumers

Strategic Sourcing and Evidence at the MSS Product Fair

Posted by Ryan Chopra on August 3, 2017

The Mid-America Service Solutions (MSS) Product Fair is being held on August 3rd at the Overland Park Convention Center, Overland Park, KS. This year, Hayes is fortunate enough to be invited to speak. I’m honored to be presenting “Strategic Sourcing: What Role Should Evidence Play?”

Read More

Sign up to receive updates from our blog

Our latest articles

New Call-to-action